Heron Therapeutics raises FY2023 oncology sales guidance; projects FY2024 EBITDA breakeven

HERON THERAPEUTICS, INC. /DE/

2023-Q3 EPS reported -$0.75 revenue$92,811,000

FY2023 net product sales guidance raised to $123-125M; oncology franchise now $104-106M.
FY2024 net product sales expected $138-158M; acute care franchise growing >48% YoY.
Gross margin forecast to improve from 41% (2023) to 69% (2024) and >75% (2025+).
Q3 2023 inventory write-offs of $7.5M; one-time expenses $4.1M; loss from ops $24.9M.
ZYNRELEF expanded label PDUFA date Jan 23, 2024; VAN program PAS submission early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HERON THERAPEUTICS, INC. /DE/ updated its three and nine months ended September 30, 2023 guidance (raised).

Period: three and nine months ended September 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On November 14, 2023, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023 (“Earnings Press Release”).

View on SEC.gov

Browse all earnings releases →

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-23-063702

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.